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INTRODUCTION
Breast cancer has variable clinical, pathologic and molecu-
lar features, resulting in diversity in behavior, response to 
therapy, and clinical outcome [1]. Breast cancer is divided into 
subtypes based on hormone receptor status and Her-2-neu 
(HER2) analysis [2]. These characteristics are commonly used 
to predict breast cancer prognosis and choose appropriate 
treatment options [3,4]. 
Heterogeneity of breast cancer is also associated with differ-
ent types of genetic alterations such as mutations in oncogenes 
and tumor suppressor genes. One of the most frequent sites of 
gene mutation is the p53 gene [5]. The p53 protein has been 
identified as a transcription factor with sequence-specific 
DNA-binding properties and the ability to regulate entry into 
the S phase of the cell cycle [6]. It plays a key role in many cel-
lular pathways and influences the induction of apoptosis in 
malignant cells [7].
The p53 gene has been described as the most mutated gene 
in breast cancer, with approximately 30% of tumors having a 
p53 mutation [5]. A recent study of The Cancer Genome Atlas 
Network evaluated whole-exome sequencing data and identi-
fied the frequency of p53 gene mutation as 37% in breast can-
cer overall and as high as 80% in basal-like breast cancer [8], 
which is characterized by expression of genes usually found in 
basal epithelial cells and it is placed within a cluster of estro-
gen receptor negative and HER2 negative tumors being asso-
ciated with poor prognosis [9,10].
The prognostic significance of p53 gene mutations has often 
been studied, but the impact of individual p53 gene mutations 
on outcomes in breast cancer remains controversial [11,12]. 
There are many types of p53 mutations, the most common 
type being missense mutation followed by frame shift, non-
sense, and others [13]. According to several studies, the influ-
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Purpose: The p53 gene is one of the most frequently mutated 
genes in breast cancer. We investigated the patterns and biologic 
features of p53 gene mutation and evaluated their clinical signifi­
cance in Korean breast cancer patients. Methods: Patients who 
underwent p53 gene sequencing were included. Mutational analy­
sis of exon 5 to exon 9 of the p53 gene was carried out using 
polymerase chain reaction­denaturing high performance liquid 
chromatography and direct sequencing. Results: A total of 497 
patients were eligible for the present study and p53 gene muta­
tions were detected in 71 cases (14.3%). Mutation of p53 was 
significantly associated with histologic grading (p<0.001), estro­
gen receptor and progesterone receptor status (p<0.001), HER2 
status (p<0.001), Ki­67 (p=0.028), and tumor size (p=0.004). 
The most frequent location of p53 mutations was exon 7 and 
missense mutation was the most common type of mutation. 
Compared with patients without mutation, there was a statistical­
ly significant difference in relapse­free survival of patients with 
p53 gene mutation and missense mutation (p=0.020, p=0.006, 
respectively). Only p53 missense mutation was an independent 
prognostic factor for relapse­free survival in multivariate analysis, 
with an adjusted hazard ratio of 2.29 (95% confidence interval, 
1.08–4.89, p=0.031). Conclusion: Mutation of the p53 gene was 
associated with more aggressive clinicopathologic characteris­
tics and p53 missense mutation was an independent negative 
prognostic factor in Korean breast cancer patients.
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ence of the type of p53 mutation on survival of breast cancer 
patients also varies [12,14]. There are few studies on the type 
and clinical significance of p53 gene mutations in Korean 
breast cancer patients. Therefore, we used DNA sequence-
based analysis to analyze the patterns and biologic features of 
p53 gene mutations and evaluated the clinical significance of 
these mutations in Korean patients with breast cancer.
METHODS
Patient selection
This study initially included 606 patients who were surgical-
ly treated for primary invasive breast cancer and who had un-
dergone p53 gene sequencing between December 2002 and 
December 2009 at Gangnam Severance Hospital, Yonsei Uni-
versity College of Medicine, Seoul, Korea. Patients who were 
treated with neoadjuvant chemotherapy and those who were 
diagnosed with recurrent or metachronous breast cancer were 
excluded from this study. Patients with ductal carcinoma in 
situ were also excluded. As a result, 497 patients were included 
in our analysis. This study was reviewed and approved by the 
Institutional Review Board (IRB) of Gangnam Severance Hos-
pital (Local IRB approval number, 2011-0253).
The clinical data of each patient were reviewed and patho-
logical findings including tumor size, tumor grade, presence of 
multifocal or multicentric disease, and the number of lymph 
node metastases were recorded. The results of estrogen recep-
tor (ER) and progesterone receptor (PR) analysis were also re-
corded. Her-2-neu status was assessed and HER2 positivity 
was defined by a score of 3+ on immunohistochemical (IHC) 
staining or HER2 gene amplification in fluorescence in situ 
hybridization. According to criteria suggested by the St. Gallen 
panelists [2], we classified breast cancer into four subtypes as 
follows: 1) luminal A: ER positive and/or PR positive, HER2 
negative, Ki-67-positive < 14%; 2) luminal B: ER positive and/
or PR positive, HER2 negative, Ki-67 ≥ 14% or HER2 positive, 
any Ki-67; 3) HER2: ER negative and PR negative, HER-2 
positive, any Ki-67; 4) Triple negative: ER negative and PR 
negative, HER2 negative, any Ki-67. The pathologic T stage 
and lymph node (N) stage were classified according to the sev-
enth edition of the American Joint Committee on Cancer clas-
sification system [15]. The modified Scarf-Bloom-Richardson 
grading system was used for tumor grading. All eligible pa-
tients were followed up for recurrence and survival. Relapse-
free survival (RFS) was defined as the time between initial di-
agnosis and locoregional recurrence, distant metastasis, or 
death from any cause related to breast cancer. Breast cancer-
specific survival (BCSS) was defined as the time between initial 
diagnosis and death from any cause related to breast cancer.
p53 mutation analysis
Mutational analysis for exon 5 to exon 9 of the p53 gene was 
carried out using polymerase chain reaction (PCR)-denatur-
ing high performance liquid chromatography (DHPLC) and 
direct sequencing. About 1 mg samples from freshly frozen 
surgical specimens and extraction of DNA was performed us-
ing the Easy-DNATM kit (Invitrogen, Carlsbad, USA) and 
used as a template for PCR. Specific primers, as shown in Ta-
ble 1, were used at 20 μmol. Each PCR was performed with an 
initial denaturation step of 5 minutes at 95°C, followed by 50 
cycles of 94°C for 10 seconds, 62°C for 10 seconds, 72°C for 15 
seconds; and 72°C for 5 minutes in a DNA thermal cycler 
(GeneAmp PCR System 2400; Perkin-Elmer, Branchburg, 
USA). Each PCR product was first screened for mutations by 
DHPLC (WAVE; Transgenomic, Omaha, USA), followed by 
sequence analysis if heteroduplex formation was detected 
[16,17]. The DHPLC device was operated according to the 
manufacturer’s instructions. For heteroduplex formation, PCR 
products were denatured at 95°C for 5 minutes and annealing 
was performed at 55°C for about 40 minutes. Afterwards, these 
products were automatically loaded into the DNASep Car-
tridge (Transgenomic) column. The column was washed with 
buffer D (75% acetonitrile solution) at 0.9 mL/min at 60°C for 
30 minutes, and stabilized using buffer A (0.1 M triethylam-
monium acetate [TEAA] solution, pH 7.0) and buffer B (0.1 M 
TEAA with 25% acetonitrile, pH 7.0) at 0.9 mL/min for 60 
minutes. The eluted DNA was detected using an ultra-violet 
light detector at a wavelength of 260 nm. Heteroduplexes and 
homoduplexes appear as separate forms in the chromatogram 
and the separation of these products was monitored on a 
computer screen. Sequencing analysis was performed using 
commercial reagents and an automated sequencer (ABI Prism 
BigDye Terminator v3.1 cycle sequencing kit and ABI 310 
Genetic Analyzer; Applied Biosystems, Foster City, USA). 
Both forward and reverse strands were sequenced to confirm 
Table 1. Primer sequence used to amplify p53 gene
                Sequence of primer
Length 
(bp)
Exon 5 Forward 5’-ATCTGTTCACTTGTGCCCTG 274
Reverse 5’-AACCAGCCCTGTCGTCTCTC
Exon 6 Forward 5’-AGGGTCCCCAGGCCTCTGAT 197
Reverse 5’-CACCCTTAACCCCTCCTCCC
Exon 7 Forward 5’-CCAAGGCGCACTGGCCTCATC 205
Reverse 5’-CAGAGGCTGGGGCACAGCAGG
Exon 8 Forward 5’-TTCCTTACTGCCTCTTGCTT 194
Reverse 5’-TGTCCTGCTTGCTTACCTCG
Exon 9 Forward 5’-CGCCGTGCAGTTATGCCTCAGATTC 279
Reverse 5’-CCCCCGCCCGGCCCCAATTGCAGGTAAAAC
bp =base pair.
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nucleotide alterations.
Data analyses and statistical methods 
Univariate analysis was performed for survival analysis of 
types of p53 mutation and the Kaplan-Meier method was ap-
plied to estimate disease-free survival and overall survival 
curves. The significance of differences between the estimated 
survival curves was tested using log-rank statistics. All statisti-
cal analyses were performed using the SPSS program version 
18.0 (SPSS Inc., Chicago, USA). A p-value less than 0.05 was 
considered to indicate a statistically significant difference.
RESULTS
Among a total of 606 patients who underwent p53 gene se-
quencing between December 2002 and December 2009, 497 
patients were eligible for the present study. Among them, p53 
gene mutations were detected in 71 cases (14.3%). The associ-
ation of p53 mutation with clinical and pathological charac-
teristics was investigated (Table 2). Mutation of p53 was sig-
nificantly associated with histologic grade (p< 0.001), estro-
gen receptor and progesterone receptor status (p < 0.001), 
HER2 status (p < 0.001), Ki-67 (p = 0.028), and tumor size 
(p= 0.004). p53 mutation was more prevalent in patients with 
high grade, hormone receptor negative, HER2 positive, and 
large tumors. Subgroup analysis showed that p53 mutation 
was observed more frequently in patients with HER2 or tri-
ple-negative breast cancer subtypes (32.4%) (p< 0.001).
Among the 71 patients with p53 mutation, the types and lo-
cations of the mutation were investigated. As shown in Figure 
1, missense mutation was the most common type of p53 muta-
tion (43 patients, 60.6%) and frame shift mutation was the sec-
ond most common (16 patients, 18.3%). Nonsense mutations 
were observed in 10 patients (11.3%), silent mutation in one 
patient (1.4%), and splicing mutation in six patients (8.5%). 
The most frequent location of p53 mutations was exon 7 (23 
patients, 32.4%), followed by exon 5 (16 patients, 22.5%) (Fig-
ure 2). Mutations in exons 6, 8, and 9 were observed in 10 
(14.1%), 10 (14.1%), and five patients (7.0%), respectively. Mu-
tation in an intron was detected in six patients (8.5%). The co-
don numbers with p53 mutation are presented in Figure 2; co-
Table 2. Clinical and pathologic characteristics of patients with p53 
mutation
Variable
p53 mutation
p-valueNegative
(n=426)
Positive
(n=71)
Mutated
(%)
Age (yr) 0.181
   <50 248 46 15.6
   ≥50 178 25 12.3
Histologic type 0.056
   Ductal 364 66 15.3
   Others 62 5 7.4
Histologic grade <0.001
   1 119 5 4.0
   2 173 31 15.2
   3 101 34 25.2
ER <0.001
   Positive 290 21 6.8
   Negative 136 50 26.9
PR <0.001
   Positive 274 19 6.5
   Negative 152 52 25.5
HER2 <0.001
   Positive 125 38 23.3
   Negative 301 33 9.9
Ki-67 (%) 0.028
   ≥14 111 27 19.6
   <14 315 44 12.3
Subtype <0.001
   Luminal A 183 7 3.7
   Luminal B 129 17 11.6
   HER2 54 24 30.8
   TNBC 60 23 27.7
T stage 0.004
   1 210 23 9.9
   2 201 48 19.3
   3 15 0 0
N stage 0.881
   0 238 38 13.8
   1 125 22 15.0
   2 45 9 16.7
   3 18 2 10.0
Chemotherapy 0.007
   Yes 345 66 16.1
Hormone therapy <0.001
   Yes 303 23 7.1
Radiation therapy 0.283
   Yes 175 26 12.9
ER=estrogen receptor; PR=progesterone receptor; HER2=human epider-
mal growth factor receptor 2; TNBC=triple-negative breast cancer.
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Figure 1. Types of p53 gene mutations in 71 patients.
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dons 175, 213, 237, 238, 241, and 331 were hot spots for muta-
tion in the present study. Frequently observed codons with p53 
mutation and the detailed contents of various mutations were 
summarized in Table 3.
During the median follow-up period of 67 months (1–146 
months), 51 patients had recurrence and 17 died from breast 
cancer. One patient already had distant metastasis at the time 
of diagnosis and she was excluded from survival analysis. In 
univariate analysis, we compared RFS and BCSS of the patients 
according to presence of p53 mutation. The 5-year RFS rates 
for patients with and without p53 mutation was 81.3% and 
92.2%, respectively, and there was a statistically significant dif-
ference (p= 0.020). The 5-year BCSS rates for patients with and 
without p53 mutation was 97.0% and 97.5%, respectively, and 
this was not statistically significant (p= 0.401). We further in-
vestigated survival according to presence of p53 missense mu-
tation. The 5-year RFS rates for patients with and without mis-
sense mutation was 77.3% and 97.0%, respectively, and there 
was a statistically significant difference in RFS between patients 
Table 3. Frequently observed codons with p53 gene mutation and de-
tails of various mutations
Codon no. DNA mutation Protein effect Mutation types
135 c.404 G>A Cys135Tyr Missense
173 c.518 T>A Val173Glu Missense
c.517 G>T Val173Leu Missense
175 c.524 G>A Arg175His Missense
193 c.578 A>G His193Arg Missense
c.578 A>T His193Leu Missense
213 c.637 C>T Arg213del Nonsense
236 c.707 A>G Tyr236Cys Missense
c.707 T>A Tyr236Asn Missense
237 c.711 G>A Met237Ile Missense
238 c.712 T>C Cys238Arg Missense
c.713 G>A Cys238Tyr Missense
c.686-687 del2 Cys238fs Frame shift
241 c.722 C>A Ser241Tyr Missense
c.722 C>T Ser241Phe Missense
242 c.724 T>G Cys242Gly Missense
c.723delC Cys242Alafsx5 Frame shift
265 c.794 T>C Leu265Pro Missense
273 c.817 C>T Arg273Cys Missense
c.818 G>A Arg273His Missense
331 c.991 C>T Gln331stop Nonsense
c.991delC Gln331fs Frame shift
Re
la
ps
e-
fre
e 
su
rv
iv
al
0 20 40 60 80 100 120 140
Follow-up period (mo)
1.0
0.8
0.6
0.4
0.2
0.0
Missense mutation
p=0.006 Negative
Positive
Figure 3. Kaplan-Meier relapse-free survival curve according to p53 
missense mutation.
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Figure 2. Locations of p53 gene mutations in 71 patients.
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with missense mutation and those without missense mutation 
(p= 0.006) (Figure 3). Missense mutation also showed mar-
ginal significance in BCSS (p= 0.060).
Multivariate analysis included tumor grade, PR, subtypes, T 
stage, N stage, p53 mutation, and missense mutation as co-
variates that showed marginally significant association with 
relapse-free survival in univariate analysis (Table 4). After ad-
justment for tumor grade, PR, subtypes, T stage, and N stage, 
presence of p53 mutation was not an independent prognostic 
factor of RFS (hazard ratio (HR), 1.70; 95% confidence inter-
val (CI), 0.86–3.36; p= 0.125). However, after adjustment for 
the same variables, p53 missense mutation was an indepen-
dent prognostic factor of RFS with a relative hazard ratio of 
2.29 (95% CI, 1.08–4.89; p= 0.031) (Table 5).
DISCUSSION
In the present study we investigated patterns of mutation 
within exon 5 and exon 9 of the p53 gene in Korean patients 
with breast cancer. Gene sequencing revealed the presence of 
p53 mutation in 14.3% of patients, with missense mutations 
the most common type of mutation. Mutations occurred 
most commonly in exon 7, and codons 175, 213, 237, 238, 
241, and 331 were hot spots of p53 mutation. 
A number of previous studies have investigated the types and 
sites of mutations in the p53 gene in breast cancer. The p53 
gene encodes three main protein domains: the transactivation 
domain, the DNA binding domain, and the oligomerization 
domain [18]. The DNA binding domain, encoded by exon 5 
and exon 8, is the most common site of p53 gene mutation, ac-
counting for approximately 90% of the p53 mutations reported 
in breast cancer [19,20]. Moreover, according to the Interna-
tional Agency of Research on Cancer (IARC) TP53 mutation 
database, the types of mutations observed indicate a high prev-
alence of missense mutations (http://www.irac.Fr/p53). These 
missense mutations are scattered throughout the coding se-
quence, but 97% of them cluster in exons encoding the DNA-
binding domain and within this domain mutation “hotspots” 
have been identified at codons 175, 245, 248, 249, 273, and 282. 
As a result, the majority of studies have focused on mutations 
occurring within exon 5 and exon 8. Our results showed that 
the “hotspot” codons of p53 mutation in our patients were dif-
ferent from those in the IARC database or previous Western 
studies and, with the exception of codon 175, the usual hotspots 
were not observed. Analysis of the type of p53 mutation 
showed that missense mutations were the most common type 
of mutations in this study but the frequency of missense muta-
tion was relatively low compared with that in the IRAC data-
base or other studies.
We found that p53 mutation was more prevalent in high-
grade, large, hormone receptor-negative, HER2-positive tu-
mors. These results were similar to those of previous studies 
[12,20]. Olivier et al. [12] reported that, in addition to tumor 
grade and hormone receptor status, p53 mutation was more 
frequent in large tumors and node-negative tumors. Consider-
ing the division of breast tumors according to the subtype 
classification, previous studies showed that p53 mutations 
were more frequently found in patients with triple-negative or 
HER2-positive breast cancer subtypes [8,21,22]. The study of 
Curtis et al. [22] involving a detailed, genome-scale analysis of 
nearly 2,000 breast cancer cases reported that p53 mutations 
were found in 34% of basal-like, 22% of HER2, 13% of lumi-
Table 4. Univariate analysis of clinicopathologic variables for relapse-
free survival in breast cancer patients
Variable p-value (log-rank test)
Age, over 50 0.299
Histology, ductal 0.484
Tumor grade 0.074
ER, positive 0.115
PR, positive 0.002
HER2, positive 0.782
Ki-67, over 14% 0.689
Subtype 0.084
p53 mutation, positive 0.020
Missense mutation, positive 0.006
T stage 0.009
N stage <0.001
ER=estrogen receptor; PR=progesterone receptor; HER2=human epider-
mal growth factor receptor 2.
Table 5. Multivariate analysis of factors associated with relapse-free 
survival (Cox proportional hazards model)
Variable Hazard Ratio 95% CI p-value
Missense mutation, positive 2.29 1.08–4.89 0.031
Tumor grade
   II 1.21 0.50–2.98 0.671
   III 1.78 0.65–4.92 0.264
PR, positive 0.27 0.12–0.62 0.002
Subtypes
   Luminal B 1.60 0.67–3.80 0.292
   HER2 0.47 0.14–1.58 0.225
   Triple negative 0.73 0.23–2.29 0.584
T stage
   II 1.03 0.55–1.92 0.932
   III 1.86 0.46–7.60 0.387
N stage
   I 1.50 0.74–3.05 0.260
   II 1.76 0.75–4.11 0.194
   III 5.14 1.79–14.76 0.002
PR=progesterone receptor; HER2=human epidermal growth factor receptor 
2; CI=confidence interval.
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nal B, and 5% of luminal A molecular subtypes. The Cancer 
Genome Atlas Network [8] reported rates of p53 mutation of 
up to 80% in the basal-like subtype, 72% in the HER2 sub-
type, 29% in the luminal B subtype, and 12% in the luminal A 
subtype. Although mutation rates were quite different from 
those reported in these studies, the present study also showed 
that p53 mutation was detected most frequently in tumors 
with triple-negative or HER2 subtypes. The discrepancies in 
the incidence and location of p53 mutations between previous 
studies and the present study may be due to ethnic differences 
in the study populations and/or heterogeneous samples and 
analytical methods (e.g., whole-exome sequencing). Further 
investigations are needed to explain these discrepancies.
There are several studies on the prognostic value of p53 
mutation types. Børresen-Dale [5] suggested that the presence 
of mutations in the DNA binding domain of p53 is associated 
with aggressive tumors and poor prognosis. Végran et al. [14] 
also suggested that only missense mutations occurring in the 
DNA binding domain were significantly associated with 
worse disease-free survival and overall survival. Alsner et al. 
[23] showed that patients with missense mutations affecting 
the DNA binding or zinc binding domains displayed a very 
aggressive phenotype with short survival. These findings are 
supported by our data showing that missense mutation of the 
p53 gene is an independent prognostic factor and is associated 
with poor clinical outcome, although overall p53 mutation 
was not an independent prognostic factor. Olivier et al. [12] 
also showed that missense mutations, especially in the DNA-
binding domain encoded by exon 5 and exon 8, and specific 
missense mutations (i.e., codon 179 and R248W) are associat-
ed with worse prognosis. However, they found that nonmis-
sense mutations in DNA-binding domains had a similar poor 
prognostic value. Moreover, additional analysis of the whole 
coding sequence in 651 cases revealed that mutations located 
outside exon 5 and exon 8 were detected in 4% of patients and 
were associated with worse prognosis compared with wild 
type. Thus, they recommended conducting mutation analysis 
on all coding exons and splicing junctions. The present study 
did not investigate all coding exons (2 to 11) and could not as-
sess the prognostic significance of p53 mutations occurring 
outside of the DNA-binding domain. A whole exon sequenc-
ing study with a large population seems to be warranted.
In summary, the present study analyzed the patterns and 
biologic features of p53 mutation types and evaluated the clin-
ical significance of these mutations in Korean patients with 
breast cancer. Our data showed that exon 7 was the most fre-
quent site of p53 mutation, and missense mutation was the 
most common type of mutation. Mutation of p53 was more 
prevalent in high-grade, large, triple-negative tumors, and 
HER2-positive tumors. Missense p53 mutation was an inde-
pendent predictive factor associated with poor prognosis. We 
need additional studies with a large number of patients for 
clinical implication of results and for explanation of the ob-
served differences in “hotspot” codons and the incidence of 
p53 gene mutation between this and other studies.
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